

Cumulated Subject Index—Vol.8, 1974

A

- Abortion
 - induced by prostaglandins 8: 161–163, 164–167, 199–200
- Acebutolol
 - hypertension 7: 94
- Acetylation
 - genetic differences 8: 306–309
- Acetylcholine hypersensitivity
 - cromoglycate 7: 201
- Acne vulgaris 8: 217–223
 - pathogenesis 8: 217
 - pregnancy 8: 218
 - treatment 8: 217–218
 - acne surgery 8: 222
 - androgen antagonists 8: 218
 - antibacterial agents 8: 221–222
 - benzoyl peroxide 8: 417–421
 - corticosteroids 8: 218–219
 - hormones 8: 218–219
 - oestrogens 8: 218
 - physical therapy 8: 219–221
- Adenocarcinoma
 - vaginal
 - due to maternal oestrogen 7: 469–470
- Adipose tissue
 - drug action 7: 141–142
 - obesity 7: 321–322
- Adrenaline
 - asthma
 - pharmacology 7: 358–360
- Adrenergic receptor blockade 8: 110–111
- Adrenergic receptors
 - β -blocking drugs 7: 9–10
 - pharmacology in asthma 7: 355
- α -Adrenergic receptor blocking drugs
 - + β -blocking drugs in hypertension 7: 94
- α -Adrenergic receptor
 - cromoglycate 7: 191–192
- β -Adrenergic receptor
 - asthma 7: 184–185
 - stimulants
 - mode of action 7: 193
- β -adrenergic receptor blocking drugs
 - absorption 7: 40
 - adrenergic receptor blockade 8: 110–111
- adverse reactions
 - airways obstruction 7: 456
 - atrioventricular conduction delay 7: 455–456
 - heart failure 7: 455
 - immunological complications 7: 457
 - sinus arrest 7: 456
- agonist activity 7: 10–11
- alcohol withdrawal 8: 117–118
- anaesthesia 7: 396–399
- angina pectoris 7: 55–84, 8: 212–213
 - antianginal activity 7: 61–63
 - dosage regulation 7: 79
 - drug trials 7: 59–61, 63–67, 73
 - + hypertension 8: 429
 - mode of action 7: 57–59
 - nitrites comparison 7: 76–78
 - precautions 7: 78–79
 - therapeutic trials 7: 67–78
 - therapeutic use 7: 80–81
 - verapamil comparison 7: 78
- anxiety states 8: 112–117
 - morbid anxiety 8: 112–116
 - physiological anxiety 8: 117
- arrhythmias 7: 426–462
 - cardiac surgery 7: 447–448
 - digitalis induced 7: 449–450
 - intrasurgical 7: 448
 - supraventricular 7: 433–438
 - ventricular 7: 442–446
- arterial pressure 7: 28
- asthma 7: 98–99, 124–125, 132–136
 - atrioventricular conduction 7: 23–24
 - available β -blocking drugs 8: 423–424
 - bioavailability 7: 40–41, 45
 - β -blocking effect 7: 10
 - blood flow 7: 24–26
 - bronchoconstriction: mechanism 7: 131
 - carbohydrate metabolism 7: 31–32
 - cardiac failure 7: 99–100, 122
 - cardiac output 7: 18–23, 26–27
 - cardiomyopathy, hypertrophic 7: 107–109
 - cardiovascular haemodynamic effects 7: 12–29
 - children 7: 45
 - clearance 7: 42–43
 - DC cardioversion 7: 446–447
 - dosage 8: 425–426
 - drug dependence 8: 118–120
 - effect on plasma renin 8: 463
 - efficacy and blood levels 8: 426–427
 - electrophysiological effect 7: 430–433
 - on membrane-depressant effect 7: 431–432
 - on pacemaker potentials 7: 430
 - elimination 7: 40–41
 - Fallot's tetralogy 7: 114–115
 - fatty acids, free 7: 31–32
 - growth hormone 7: 32–33
 - haematological reactions 7: 126
 - half-life, excretion 7: 42–43
 - heart rate: effect on 7: 15–18

Cumulated Subject Index—Vol.8, 1974

A

- Abortion
 - induced by prostaglandins 8: 161–163, 164–167, 199–200
- Acebutolol
 - hypertension 7: 94
- Acetylation
 - genetic differences 8: 306–309
- Acetylcholine hypersensitivity
 - cromoglycate 7: 201
- Acne vulgaris 8: 217–223
 - pathogenesis 8: 217
 - pregnancy 8: 218
 - treatment 8: 217–218
 - acne surgery 8: 222
 - androgen antagonists 8: 218
 - antibacterial agents 8: 221–222
 - benzoyl peroxide 8: 417–421
 - corticosteroids 8: 218–219
 - hormones 8: 218–219
 - oestrogens 8: 218
 - physical therapy 8: 219–221
- Adenocarcinoma
 - vaginal
 - due to maternal oestrogen 7: 469–470
- Adipose tissue
 - drug action 7: 141–142
 - obesity 7: 321–322
- Adrenaline
 - asthma
 - pharmacology 7: 358–360
- Adrenergic receptor blockade 8: 110–111
- Adrenergic receptors
 - β -blocking drugs 7: 9–10
 - pharmacology in asthma 7: 355
- α -Adrenergic receptor blocking drugs
 - + β -blocking drugs in hypertension 7: 94
- α -Adrenergic receptor
 - cromoglycate 7: 191–192
- β -Adrenergic receptor
 - asthma 7: 184–185
 - stimulants
 - mode of action 7: 193
- β -adrenergic receptor blocking drugs
 - absorption 7: 40
 - adrenergic receptor blockade 8: 110–111
- adverse reactions
 - airways obstruction 7: 456
 - atrioventricular conduction delay 7: 455–456
 - heart failure 7: 455
 - immunological complications 7: 457
 - sinus arrest 7: 456
- agonist activity 7: 10–11
- alcohol withdrawal 8: 117–118
- anaesthesia 7: 396–399
- angina pectoris 7: 55–84, 8: 212–213
 - antianginal activity 7: 61–63
 - dosage regulation 7: 79
 - drug trials 7: 59–61, 63–67, 73
 - + hypertension 8: 429
 - mode of action 7: 57–59
 - nitrates comparison 7: 76–78
 - precautions 7: 78–79
 - therapeutic trials 7: 67–78
 - therapeutic use 7: 80–81
 - verapamil comparison 7: 78
- anxiety states 8: 112–117
 - morbid anxiety 8: 112–116
 - physiological anxiety 8: 117
- arrhythmias 7: 426–462
 - cardiac surgery 7: 447–448
 - digitalis induced 7: 449–450
 - intrasurgical 7: 448
 - supraventricular 7: 433–438
 - ventricular 7: 442–446
- arterial pressure 7: 28
- asthma 7: 98–99, 124–125, 132–136
 - atrioventricular conduction 7: 23–24
 - available β -blocking drugs 8: 423–424
 - bioavailability 7: 40–41, 45
 - β -blocking effect 7: 10
 - blood flow 7: 24–26
 - bronchoconstriction: mechanism 7: 131
 - carbohydrate metabolism 7: 31–32
 - cardiac failure 7: 99–100, 122
 - cardiac output 7: 18–23, 26–27
 - cardiomyopathy, hypertrophic 7: 107–109
 - cardiovascular haemodynamic effects 7: 12–29
 - children 7: 45
 - clearance 7: 42–43
 - DC cardioversion 7: 446–447
 - dosage 8: 425–426
 - drug dependence 8: 118–120
 - effect on plasma renin 8: 463
 - efficacy and blood levels 8: 426–427
 - electrophysiological effect 7: 430–433
 - on membrane-depressant effect 7: 431–432
 - on pacemaker potentials 7: 430
 - elimination 7: 40–41
 - Fallot's tetralogy 7: 114–115
 - fatty acids, free 7: 31–32
 - growth hormone 7: 32–33
 - haematological reactions 7: 126
 - half-life, excretion 7: 42–43
 - heart rate: effect on 7: 15–18

- heart syndrome, hyperkinetic 7: 110-114
- hypertension 7: 85-105, 8: 85, 408-410
 - + angina 8: 429
 - clinical use 7: 96-98
 - combined with other drugs 7: 94
 - dosage 7: 94
 - drug trials 7: 89-90
 - mild to moderate 8: 430
 - mode of action 7: 87, 8: 424-427
 - plasma levels 7: 94
 - precautions 7: 97-98
 - reasons for use 7: 97
 - severe 8: 428-429
- hyperthyroidism 7: 48-54
- hypoglycaemic reactions 7: 126
- indications for use 8: 427-431
 - advantages 8: 427
 - disadvantages 8: 427-428
- libido 7: 101
- lithium-induced tremor 8: 121
- liver disease: elimination 7: 45
- metabolic effects 7: 30-33
- metabolism 7: 41-42
- myocardial infarction 7: 442-446
- pacemakers, artificial 7: 449
- pharmacology 7: 1-7
 - pharmacodynamics 7: 8-38
- pharmacokinetics 7: 39-47
 - plasma binding 7: 43
 - plasma concentrations 7: 43-45, 94
 - plasma volume 7: 29
- psychiatric effects 7: 100-101, 125
- psychiatry 8: 111-112
- quinidine-like effect 7: 11-12
- Raynaud's phenomenon 7: 101
- renal disease: elimination 7: 45
- renin activity, plasma 7: 30
- respiratory function 7: 130-138
- schizophrenia 8: 120-121
- selectivity of activity 7: 12
- side-effects 7: 98-102
 - 118-127, 130-137 8: 121-124, 426
 - determinants 7: 120-121
 - epidemiological studies 7: 122-124
 - severity 7: 120-121
- sodium excretion, renal 7: 29-30
- therapeutic use 7: 1-7, 8: 428-431
 - cautions 8: 428
 - which β -blocking drug? 8: 430-431
- + tricyclic antidepressants 8: 409
- tricyclic antidepressant overdosage 7: 399-400
- + vasodilator 8: 409
- ventricular function 7: 26-27
- weight gain 7: 102
- Adrenocortical function
 - in surgery 8: 234-236
- Airways calibre
 - asthma 7: 350-355
- Alcohol
 - causing asthmatic reaction 7: 403-404
- Alcoholism
 - β -blocking drugs 8: 117-118
 - propranolol 7: 140
- Alfathesin 8: 87-88
 - animal studies 8: 99-102
 - anaesthetic properties 8: 99-100
 - dysmorphology studies 8: 102
 - effect on central nervous system 8: 101
 - effect on veins 8: 100-101
 - haemodynamic effects 8: 100
 - hormonal effects 8: 101
 - interaction with other anaesthetics 8: 101-102
 - clinical pharmacology 8: 93-99
 - anaesthetic effect 8: 93-94
 - analgesic effect 8: 98-99
 - cardiovascular effects 8: 94-96
 - effect on muscle 8: 94
 - effect on veins 8: 97
 - respiratory effects 8: 96-97
 - use with other anaesthetics 8: 97
 - clinical studies 8: 88-93
 - cardioversion 8: 93
 - dental anaesthesia 8: 92
 - induction of anaesthesia 8: 89-90
 - intra-ocular surgery 8: 92-93
 - obstetrics 8: 93
 - psychiatry 8: 92
 - sole anaesthetic agent 8: 90
 - dosage 8: 106
 - pharmacokinetic studies: animal 8: 102-103
 - distribution 8: 102-103
 - excretion 8: 103
 - metabolism 8: 103
 - plasma levels 8: 102
 - protein binding 8: 103
 - pharmacokinetic studies: human 8: 99
 - precautions 8: 105
 - side-effects 8: 82, 104-105
- Allergy
 - asthma 7: 177-184, 348-349
- Allergy testing
 - asthma 7: 385
- Allopurinol
 - interaction with cytotoxic drugs 8: 458-459
 - renal calculi 8: 67
- Alphadolone acetate
 - combined with alphaxalone 8: 87-108
- Alphaxalone
 - combined with alphadolone acetate 8: 87-108
- Alprenolol
 - absorption 7: 40
 - angina pectoris 7: 61, 67-69, 75-76, 78
 - arrhythmias 7: 425-453
 - asthma 7: 132-136
 - bioavailability 7: 40-41
 - clearance 7: 42-43
 - elimination 7: 40
 - half-life, clearance 7: 42-43
 - heart syndrome, hyperkinetic 7: 110
 - hypertension 7: 92, 96-98 8: 422-431
 - hyperthyroidism 7: 50
 - pharmacodynamics 7: 8-38
 - plasma binding 7: 43
 - respiratory function 7: 130-136
 - side-effects 7: 98-102

- Althesin
see alfathesin
- Aminophylline, intravenous
adverse reactions 7: 404-405
overdosage 7: 404-405
- Amitriptyline
associated with weight gain 8: 229-230
side-effects 8: 229-230
poisoning in children 7: 470-471
- Amoxycillin 7: 326-336
absorption 7: 328-329
antibacterial activity 7: 327
with other antibacterial agents 7: 327
contra-indications 7: 334
distribution 7: 330
dosage 7: 335
excretion 7: 330
gonorrhoea 7: 333-334
pharmacokinetics 7: 328-330
precautions 7: 335
protein binding 7: 330
respiratory infections 7: 331-332
side-effects 7: 334
skin and soft tissue infections 7: 334
therapeutic efficacy 7: 331-334
urinary infections 7: 332-333
- Anaemia, aplastic
drug-induced 8: 147-148
- Anaesthesia
alfathesin 8: 87-108
- Anaesthesia, dental
alfathesin 8: 92
- Anaesthesia, general
in hypertension 7: 396-399, 8: 84-86
- Anaesthetic gases
effect on psychomotor skills 8: 318-319
- Anaesthetics
effect on psychomotor skills 8: 461-462
side-effects 8: 81-83
- Anaesthetics: intravenous
alfathesin 8: 87-108
side-effects 8: 82-83
- Analgesic nephropathy 8: 238
- Analgesics
ketoprofen 8: 168-175
- Androgens
clinical applications
metabolic bone disease 8: 268-269
erythropoiesis 7: 150-151
mode of action 8: 268
- Angina pectoris
drug trials 7: 59-61, 63-67, 73
- Angina pectoris: management 8: 208-216
aggravating factors 8: 210-211
emotional stress 8: 210
strenuous arm activity 8: 211
sudden effort 8: 210-211
 β -blocking drugs 7: 55-84, 8: 212-213
dosage 8: 213
precautions 8: 212-213
rationale for use 8: 212
side-effects 8: 213
congestive heart failure 8: 216
- crescendo angina 8: 215
diet 8: 209
digitalis 8: 213-214
diuretics 8: 214
drug therapy 8: 211-214
education of patient 8: 208
glyceryl trinitrate 8: 211
intractable angina 8: 215-216
isosorbide dinitrate 8: 211
physical activity 8: 209-210
treatment of arrhythmias 8: 214-215
- Ankylosing spondylitis
complications 8: 454-455
diagnosis 8: 448-449
management 8: 449-454
change of occupation 8: 450
continued assessment 8: 454
drug therapy 8: 452-453
exercise 8: 450
general 8: 449-450
laboratory tests 8: 451
neck and spine care 8: 450-451
plantar fasciitis and periostitis 8: 451
radiotherapy 8: 453
surgical treatment 8: 453-454
uveitis 8: 451
prognosis 8: 455
- Antacids
evaluation 8: 225-226
peptic ulcer therapy 8: 224-225
- Antiasthmatic drugs 7: 344-369
pharmacokinetics 7: 365
pharmacology 7: 358-365
therapeutic use 7: 370-390
in children 7: 386-387
- Antibacterial agents
therapeutic efficacy
meningitis 8: 30-37, 42-48
- Antibiotics, broad spectrum
amoxycillin 7: 326-336
- Antibodies
carriers of anticancer agents? 8: 460-461
- Anticancer agents
antibodies as carriers? 8: 460-461
- Anticonvulsant drugs
adverse reactions 7: 394-395
changes in plasma levels
altered patient response 8: 394
changed dosage 8: 394
clinical significance 8: 392-394
non-significant changes 8: 392-393
congenital malformations 8: 358-360, 366-385
effect on folate metabolism 8: 380-381
folic acid deficiency 8: 372-376
meningitis 8: 38
oncogenic potential 8: 309
pharmacokinetics 8: 387-390
biologically active metabolites 8: 388-389
drug concentrations in body fluids 8: 390
plasma levels 8: 387-388, 390-394
sub-therapeutic 8: 392
therapeutic range 8: 390-391
toxic 8: 391-392

- Anticonvulsant therapy**
 laboratory control 8: 386-397
 adjustment of dosage 8: 396
 clinical application 8: 395
 initial dosage 8: 395-396
 maintenance dosage 8: 396-397
 practical implementation 8: 395-397
- Antidepressants, tricyclic**
 action on cardiovascular system 8: 433-434
 continuation therapy 7: 147
 use in elderly 8: 134
 with β -blockers 8: 409
- Antidepressants, tricyclic: overdosage 8: 432-437**
 cardiovascular abnormalities 7: 323-325
 management 8: 434-437
 atrioventricular block 8: 435
 β -blockade 7: 399-400
 cardiovascular complications 8: 434-436
 hypotension 8: 436-437
 intravenous potassium 8: 436
 prolonged intraventricular conduction 8: 435
 reduce absorption 8: 434
 respiratory complications 8: 436
 sodium bicarbonate 8: 436
 supraventricular tachycardia 8: 434-435
 ventricular arrhythmia 8: 435-436
- Antihypertensive drugs**
 β -blockers 8: 422-431
 elderly 7: 310-317
- Anti-inflammatory agents**
 ketoprofen 8: 168-175
- Antiparkinsonian drugs**
 dyskinesia, tardive 7: 142
- Anxiety**
 beta-blocking drugs 8: 112-116
 treatment in elderly 8: 136
- Aplastic anaemia**
 see anaemia, aplastic
- Arrhythmias, cardiac**
 alprenolol 7: 452-453
 β -blockers 7: 433-442, 447-450
 electrophysiology 7: 429-430
 oxprenolol 7: 453
 pindolol 7: 453-454
 practolol 7: 454-455
 propranolol 7: 451-452
 treatment in angina 8: 214-215
 tricyclic antidepressant overdosage 7: 323-325
- Aspirin**
 causing analgesic nephropathy 8: 238
 treatment in adults 7: 376-381
 treatment in children 7: 386-387
- Asthma**
 adrenergic receptors 7: 184-185
 pharmacology 7: 355
 aetiology 7: 176-184
 airways calibre 7: 350-355
 allergic mechanisms 7: 177-184, 348-349
 antigen-induced
 cromoglycate 7: 194-198
 assessment 7: 373-376
 non-response to previous therapy 7: 373-374
 patient history 7: 373
 physical signs 7: 374-376
 β -blocking drugs 7: 98-99, 124-125
 cromoglycate 7: 164-282
 cyclic AMP 7: 355
 drug trials 7: 209-214
 cromoglycate 7: 214-219
 epidemiology 7: 349-350
 exercise
 cromoglycate 7: 254-260
 extrinsic 7: 178-183
 functional changes 7: 347-348
 humoral agents
 prostaglandins 7: 352-353
 slow reacting substance of anaphylaxis 7: 352
 humoral factors 7: 350-355
 bradykinin 7: 351-352
 histamine 7: 350-351
 mast cell 7: 353-355
 serotonin 7: 353
 intrinsic 7: 183-184
 maintenance therapy
 in adults 7: 381-385
 in children 7: 388
 pathology 7: 346-347
 pharmacological mechanisms 7: 350-357
 respiration, control of 7: 355-357
 treatment, aims of 7: 372-373
 treatment in children 7: 385-388
- Asthma, chronic**
 treatment
 beclomethasone 8: 315-316
 corticosteroids 8: 241-245, 314-315
 corticotrophin 8: 314-315
 prednisone 8: 315-316
- Azathioprine**
 hepatitis 8: 141
- B**
- Baclofen 8: 1-14**
 absorption 8: 10
 animal pharmacology 8: 8
 clinical experimental studies 8: 2-3
 contra-indications 8: 12
 distribution 8: 10-11
 dosage 8: 13
 excretion 8: 11
 metabolism 8: 11
 mode of action 8: 8-10
 overdosage 8: 13
 pharmacokinetics 8: 10-11
 precautions 8: 12-13
 side-effects 8: 11-12
 spasticity 8: 4-8
 therapeutic trials 8: 4-8
 open trials 8: 5-8
 placebo controlled 8: 4-5
- Bacterial meningitis**
 see meningitis
- BCG**
 immunotherapy 8: 402-403, 406

- Beclomethasone
 compared with prednisone 8: 315-316
 therapeutic use
 chronic asthma 8: 241-245
 in hay fever 7: 478-479
 Bell's palsy 8: 463-464
 Benzoyl peroxide 8: 417-421
 application 8: 420-421
 pharmacology 8: 419-420
 precautions 8: 420
 rationale for use 8: 418
 side-effects 8: 420
 therapeutic trials 8: 418-419
 Beta-blocking drugs
 see β -adrenergic receptor blocking drugs
 Betamethasone 17-valerate
 chronic asthma 8: 241-245
 Biliary tract disease
 corticosteroids 8: 145
 Biosavailability
 β -blocking drugs 7: 40-41
 digoxin 7: 467-468, 468-469
 tetracycline 7: 465-466
 Bone disease, metabolic: diagnosis
 parathyroid hormone 8: 253-255
 Bone disease, metabolic: pharmacology 8: 250-289
 androgens 8: 268
 calcitonin 8: 256-257
 diphosphonates 8: 276-277
 diuretics 8: 281-283
 fluoride 8: 280
 glucocorticosteroids 8: 265-266
 mithramycin 8: 269-271
 oestrogens 8: 268
 phosphate 8: 274
 vitamin D 8: 262-264
 Bone disease, metabolic: treatment 8: 246-249, 250-289
 androgens 8: 268-269
 calcitonin 8: 257-261
 calcium 8: 278-279
 diphosphonates 8: 277-278
 diuretics 8: 281-283
 fluoride 8: 280
 glucocorticosteroids 8: 266-268
 mithramycin 8: 271-273
 oestrogens 8: 268-269
 phosphate 8: 274-276
 sulphates 8: 278
 vitamin D 8: 264-265
 Bradykinin
 asthma 7: 351-352
 Breast cancer
 diagnosis 8: 310-311
 treatment 8: 311-313
 chemotherapy 8: 312
 immunotherapy 8: 312-313
 Breast tumours
 contraceptives, oral 7: 143-144
 Bronchodilators
 asthma
 maintenance therapy 7: 381-383
 pharmacology 7: 358-361
 asthma, acute 7: 376-377
 Butyrophenones
 use in elderly 8: 135-136

 C
 Calcitonin
 clinical applications
 hypercalcaemia 8: 257
 osteoporosis 8: 261
 metabolic bone disease 8: 278-279
 Paget's disease 8: 259-261
 mode of action 8: 256-257
 Calcium metabolism
 pharmacology 8: 250-289
 Calcium stones
 see renal calculi
 Cancer: treatment
 immunotherapy 8: 401-404, 405-407, 411-416
 Carbenoxolone
 compared with deglycyrrhizinated liquorice 8: 331-333
 Carbohydrate metabolism
 β -blocking drugs 7: 31-32
 Carbonic anhydrase inhibitors
 metabolic bone disease 8: 283
 Cardiac abnormality
 risks in dental treatment 7: 479-480
 Cardiac arrhythmias
 see arrhythmias
 Cardiac failure
 β -blocking drugs 7: 99-100
 Cardiogenic shock
 dopamine 8: 154-155
 Cardiomyopathy, hypertrophic
 β -blocking drugs 7: 107-109
 Cardiovascular system
 tricyclic antidepressants 8: 432-437
 Cardioversion
 alfathesin 8: 93
 β -blockers 7: 446-447
 Cellulose phosphate
 nephrolithiasis 8: 276
 Cerebrospinal fluid
 meningitis 8: 25
 Chemoreceptors
 asthma
 pharmacology 7: 355-357
 Children
 asthma 7: 385-388
 phenytoin dosage 7: 392-393
 Chloroquine
 porphyria cutanea tarda 8: 152
 Cholangiohepatitis
 corticosteroids 8: 145
 Cholestyramine
 paracetamol poisoning 7: 139
 Chorea
 trihabazine 7: 477-478
 Cirrhosis
 corticosteroids 8: 144

- Colitis, ulcerative
salicylazosulphapyridine metabolism 7: 463-464
- Combination therapy
with corticosteroids 8: 445-446
- Condyloma acuminatum
treatment 7: 154-155
- Congenital malformations
aetiology in epilepsy 8: 358
anticonvulsants 8: 358-360
genetic factors 8: 361-362
severity of epilepsy 8: 360-361
socio-economic factors 8: 361
anticonvulsants 8: 366-385
phenytoin 8: 340-353
- Connective tissue disease
corticosteroids 8: 443-444
- Contraceptive device
prostaglandins 8: 196-197
- Contraceptives, oral
breast tumours 7: 143-144
gall-bladder disease 7: 143-144
haemolytic uraemic syndrome 7: 145
myocardial infarction 7: 142-143
thrombo-embolism, venous 7: 143-144
- Corticosteroids
acne vulgaris 8: 218-219
asthma
maintenance therapy 7: 383-384
pharmacology 7: 363-364
asthma, acute 7: 377-381
asthma, chronic 8: 241-245
clinical use
biliary tract disease 8: 145
cholangiohepatitis 8: 145
cholestasis 8: 139-140
chronic hepatitis 8: 140
cirrhosis 8: 144
drug-induced liver disease 8: 144
extrahepatic obstruction 8: 145
fulminant hepatitis 8: 140
hepatitis, active chronic 8: 140-143
liver disease 8: 139-145
viral hepatitis 8: 139
compared with corticotrophin 8: 314-315
injection therapy in rheumatology 8: 316-317
meningitis 8: 38
mode of action 7: 192-193
side-effects 8: 439
- Corticosteroids, inhaled
asthma 7: 384
pharmacology 7: 384
- Corticosteroids in renal disease 8: 438-447
acute metabolic effects 8: 446
combination therapy 8: 445-446
connective tissue disease 8: 443-444
hypersensitivity angitis 8: 444
polyarteritis nodosa 8: 444
systemic lupus erythematosus 8: 443-444
systemic sclerosis 8: 444
Goodpasture's syndrome 8: 445
interstitial nephritis 8: 444-445
minimal lesion nephrotic syndrome 8: 440-443
results of therapy 8: 440-442
role of cyclophosphamide 8: 440
therapeutic regimen 8: 442-443
renal transplantation 8: 445
Wegener's granulomatosis 8: 445
when not to use 8: 446
- Corticosteroids, topical
adverse reactions 8: 70-77
adverse reactions, local 8: 71-75
allergy 8: 75
atrophy 8: 74-75
face lesions 8: 71-72
hypertrichosis 8: 75
infection 8: 73-74
ulceration 8: 75
adverse reaction, systemic 8: 75-77
fluocinonide 7: 337-343
- Corticotrophin
asthma 7: 384
pharmacology 7: 364-365
compared with corticosteroids 8: 314-315
- Counter-immuno-electrophoresis 8: 26
- Cromoglycate, sodium
absorption 7: 206-207
acetylcholine hypersensitivity 7: 201
 α -adrenergic receptor 7: 191-192
asthmatic reactions to alcohol 7: 403-404
atropine, bronchial responsiveness 7: 201-202
bronchodilator usage 7: 225-226
corticosteroid-sparing 7: 226, 260-267
distribution 7: 207-209
dosage 7: 270-272
dysmorphology 7: 205
excretion 7: 207-209
exercise asthma 7: 254-260
guidelines for use 7: 174-175
histamine hypersensitivity 7: 191-192, 200-201
lung function 7: 227-238
mast cells 7: 188-191
metabolism 7: 209
mode of action 7: 185-194
compared with
 β -adrenergic receptor stimulants 7: 193
corticosteroids 7: 192-193
methylxanthines 7: 193-194
nasal obstruction, antigen-induced 7: 198-200
pharmacokinetics 7: 206-209
pharmacology, animal 7: 202-205
pharmacology, clinical 7: 194-202
placental transfer 7: 209
precautions 7: 269-270
protein composition, sputum 7: 202
rationale for use 7: 176-194
response to
age 7: 248-249
allergy 7: 249-252
asthma severity 7: 252-253
eosinophilia 7: 253
lability index 7: 254
prediction of 7: 267-268
side-effects 7: 268-269
therapeutic efficacy
adults 7: 219-223, 238-243
children 7: 223-225, 243-248

- toxicity 7: 203-205
 Cromoglycate, sodium: asthma 7: 164-282
 antigen-induced 7: 194-198
 clinical use 7: 161-163, 174-175
 maintenance therapy 7: 383
 pharmacology 7: 362
 Cromoglycate, sodium: gastro-intestinal
 protein intolerance 7: 293-294
 Cromoglycate, sodium: kerato-conjunctivitis, vernal 7:
 294
 Cromoglycate, sodium: nasal polyps 7: 295
 Cromoglycate, sodium: rhinitis, allergic 7: 283-293
 antihistamine requirements 7: 290
 dosage 7: 293
 eye symptoms 7: 287-290
 nasal symptoms 7: 287
 response to 7: 285, 291
 side-effects 7: 293
 therapeutic efficacy 7: 286-291
 Cromoglycate, sodium: rhinitis, perennial 7: 291-293
 Cromolyn
 see cromoglycate, sodium
 Cyclic AMP
 asthma 7: 355
 Cysteamine
 paracetamol overdose 8: 457-458
 Cystine stones
 see renal calculi
 Cytotoxic drugs
 interaction with allopurinol 8: 458-459
- D**
- Deglycyrrhizinised liquorice
 dosage 8: 339
 pharmacology 8: 336-338
 antispasmodic activity 8: 337
 metabolic effects 8: 338
 mode of action 8: 337
 prevention of ulcer formation 8: 337-338
 side-effects 8: 338-339
 therapeutic trials 8: 331-336
 combined with antacids 8: 336
 duodenal ulcer 8: 333-336
 gastric ulcer 8: 331-333
 Dental anaesthesia
 see anaesthesia: dental
 Dental treatment
 in cardiac abnormality 7: 479-480
 Depression
 antidepressants, tricyclic: continuation 7: 147
 β -blocking drugs 7: 101
 treatment in elderly 8: 134
 Dermatological vehicles
 see vehicles, dermatological
 Dermatoses, inflammatory
 fluocinonide 7: 342
 Diabetes
 with myocardial infarction 8: 237
 Diethylstilboestrol
 adverse reactions 7: 469-470
- Digitalis
 angina 8: 213-214
 Digitalis glycosides
 pharmacokinetics 7: 482-485
 Digoxin
 bioavailability tests 7: 467-468, 468-469
 Diphenylhydantoin
 see phenytoin
 Diphosphonates
 adverse effects 8: 277-278
 metabolic bone disease 8: 277
 mode of action 8: 276-277
 Paget's disease 8: 242
 Diuretics
 + β -blocking drugs in hypertension 7: 94
 mefruside 7: 419-425
 therapeutic use
 metabolic bone disease 8: 281-283
 Dizziness
 questionnaire 7: 300-301
 Dopamine
 cardiogenic shock 8: 154-155
 Drug advertising 7: 412-413, 417-418
 Drug control 7: 412-413
 Drug dependence
 β -blocking drugs 8: 118-120
 Drug induced disease
 adenocarcinoma 7: 469-470
 aplastic anaemia 8: 147-148
 Drug information 8: 321-329
 international uniformity 8: 327-329
 national differences 8: 321-322
 uniformity of content 8: 322-326
 Drug interactions
 alfathesin/anaesthetics 8: 101-102
 + allopurinol 8: 458-459
 + cytotoxic drugs 8: 458-459
 guanethidine/chlorpromazine 7: 139
 + ketoprofen 8: 174
 Drug labels 7: 414-418
 advertising 7: 417-418
 contents 7: 415-417
 primary function 7: 414-415
 Drug marketing
 advertising 7: 412-413
 control 7: 412-413
 drug testing
 in animals 7: 409-410
 in man 7: 410-412
 legislation 7: 409
 patient information 7: 413
 Drug medication
 non-compliance 7: 391-392
 Drug metabolism
 by acetylation 8: 308-309
 gold 7: 399
 modified by intestinal flora 8: 227
 paracetamol 8: 457-458
 phenytoin 7: 393-394
 tricyclic antidepressants 7: 323-325, 399-400
 Drug product information 7: 414-418
 Drug reactions, adverse
 alfathesin 8: 82, 104-105

- aminophylline 7: 404-405
- amitriptyline 8: 229-230
- amoxycillin 7: 334
- anaesthetics 8: 81-83
- anticonvulsants 7: 394-399
- aspirin 8: 238
- baclofen 8: 11-12
- benzoyl peroxide 8: 420
- β -blocking drugs 7: 98-102, 118-127
- contraceptives, oral 7: 142-146
- corticosteroids 8: 439, 70-77
- deglycyrrhizinated liquorice 8: 338-339
- diethylstilboestrol 7: 469-470
- diphosphonates 8: 277-278
- enflurane 8: 230-231
- glucocorticosteroids 8: 267-268
- hospitalised patients 7: 146
- ketoprofen 8: 173
- mefruside 7: 424-425
- methoxyflurane nephrotoxicity 7: 400-403
- methramycin 8: 273
- oestrogen 7: 469-470
- pentazocine 8: 149-150
- pheniramine 7: 471-472
- phenytoin 7: 395-396
- phosphate 8: 276
- rifampicin 8: 148-149, 228-229
- salicylazosulphapyridine 7: 462-463
- Drug regimens
 - non-compliance 7: 391-392
- Drug trials 7: 409-412
 - asthma 7: 209-214
 - cromoglycate 7: 214-219
 - β -blocking drugs
 - angina pectoris 7: 59-61, 63-67, 73
 - hypertension 7: 89-90
 - in animals 7: 409-410
 - in man 7: 410-411
 - mefruside 7: 422-424
- Duodenal ulcer
 - deglycyrrhizinated liquorice 8: 333-336
- Dyskinesia, tardive
 - antiparkinsonian drugs 7: 148
- Dysmorphogenesis
 - phenytoin 8: 340-353
- E
 - Eclampsia 8: 129-130
 - Ectopics, supraventricular
 - β -blocking drugs 7: 433-434
 - Ectopics, ventricular
 - β -blocking drugs 7: 438-439
 - Eczema
 - fluocinonide 7: 339-341
 - with varicose ulcers 8: 156-157
 - Elderly
 - antihypertensive therapy 7: 310-317
 - psychotherapeutic drugs 8: 132-138
 - Enflurane
 - in renal disease 8: 230-231
 - side-effects 8: 230-231
 - Ephedrine
 - asthma
 - pharmacology 7: 360
 - Epidermolysis bullosa
 - vitamin E therapy 8: 319, 462
 - Epilepsy
 - dysmorphogenic potential of phenytoin
 - 8: 340-353
 - folic acid deficiency 8: 366-385
 - incidence in pregnancy 8: 355-356
 - laboratory control of therapy 8: 386-397
 - Erythropoiesis
 - androgens 7: 150-151
 - Ethacrynic acid
 - metabolic bone disease 8: 281
 - Exercise
 - asthma
 - cromoglycate 7: 254-260
- F
 - Facial hyperkinesis 8: 459-460
 - Fatty acids, free
 - β -blocking drugs 7: 31-32
 - Fibrillation, atrial
 - β -blocking drugs 7: 436-437
 - Fibrillation, ventricular
 - β -blocking drugs 7: 440-442
 - Fluocinonide 7: 337-343
 - administration 7: 342
 - contra-indications 7: 342
 - dermatoses, inflammatory 7: 342
 - eczema 7: 339-341
 - experimental studies 7: 338-339
 - precautions 7: 342
 - psoriasis 7: 341
 - side-effects 7: 342
 - therapeutic trials 7: 339-342
 - Fluoride
 - clinical applications
 - myeloma 8: 280
 - osteoporosis 8: 280
 - mode of action 8: 280
 - toxicity 8: 280
 - Flutter, atrial
 - β -blocking drugs 7: 437-438
 - Folate metabolism 8: 367-372
 - absorption 8: 371
 - development of folate deficiency 8: 371-372
 - effect of phenytoin 8: 363
 - folate forms 8: 367-368
 - in body fluids 8: 370-371
 - in the central nervous system 8: 379-381
 - blood folic acid 8: 379-380
 - cerebrospinal fluid 8: 380
 - effect of anticonvulsants 8: 380-381
 - metabolic importance 8: 369-370
 - Folic acid deficiency
 - dysmorphogenic potential of phenytoin 8: 340-353
 - in epilepsy 8: 375-376
 - neurological complications 8: 374-378

- practical implications 8: 382
- psychiatric implications 8: 376–378
- related to anticonvulsants 8: 373–374
- role of folic acid 8: 372–373

- Food additives
 - causing purpura 8: 234

- Frusamide
 - in acute renal failure 7: 475–476
 - therapeutic use
 - metabolic bone disease 8: 281

G

- Gall-bladder disease
 - contraceptives, oral 7: 143–144
- Gastric acid
 - H₂-receptors 8: 226–227
- Gastric ulcer
 - deglycyrrhizinised liquorice 8: 331–333
- Gentamicin
 - gram-negative sepsis 8: 307–308
 - monitoring therapy 8: 307–308
- Geriatric pharmacology
 - antihypertensive drugs 7: 310–317
 - psychotherapeutic drugs 8: 132–138
- Gingival hyperplasia
 - see hyperplasia, gingival
- Glucocorticoids
 - effect in surgery 8: 234–236
- Glucocorticosteroids
 - administration 8: 267
 - adverse effects 8: 267–268
 - clinical applications
 - metabolic bone disease 8: 266–268
 - mode of action 8: 265–266
- Glucose
 - meningitis 8: 25–26
- Glycerol trinitrate
 - angina 8: 211
- Gold
 - serum levels 7: 399
- Gonorrhoea
 - amoxycillin 7: 333–334
 - diagnosis in women 7: 156
- Goodpasture's syndrome
 - corticosteroids 8: 445
- Gout, pseudo
 - elderly 7: 151–152
- Growth hormone
 - β -blocking drugs 7: 32–33
- Guanethidine
 - chlorpromazine interaction 7: 139

H

- H₂-receptors
 - see histamine receptors
- H. influenza meningitis
 - see meningitis

- Haemolysis
 - due to rifampicin 8: 148–149
- Haemolytic uraemic syndrome
 - contraceptives, oral 7: 145
- Halofenate
 - uricosuric action 8: 146
- Halothane
 - causing jaundice 8: 81–82
 - effect on psychomotor skills 8: 461–462
- Hay fever
 - beclomethasone, intranasal 7: 478–479
- Heart syndrome, hyperkinetic
 - β -blocking drugs 7: 110–114
- Heparin
 - prevention of thrombosis 8: 152–153
- Hepatitis
 - corticosteroids 8: 140–143
 - due to rifampicin 8: 228–229
- Hepatotoxicity 8: 228–229
 - halothane 8: 81–82
- Histamine
 - asthma 7: 350–351
- Histamine hypersensitivity
 - cromoglycate 7: 191–192, 200–201
- Histamine receptors
 - gastric acid 8: 226–227
- Hydatiform mole
 - prostaglandins 8: 200
- Hydrocortisone
 - fulminant hepatitis 8: 140
- Hypercalcaemia
 - management 8: 249
 - treatment 8: 250–289
 - calcitonin 8: 257
 - glucocorticosteroids 8: 266–267
 - nithramycin 8: 272–273
 - phosphate 8: 274–275
 - sulphates 8: 278
- Hypercalciuria
 - treatment 8: 250–289
 - diuretics 8: 281–283
- Hyperoxaluria
 - treatment 8: 68–69
- Hyperparathyroidism
 - confused with osteoporosis 8: 298–299
- Hyperplasia, gingival
 - phenytoin 7: 395–396
- Hypertension
 - anaesthesia 7: 396–399, 8: 84–86
 - assessment of risk factors 8: 313–314
 - β -blocking drugs 7: 85–105, 8: 408–410, 422–431
 - elderly
 - treatment 7: 310–317
 - in pregnancy 8: 125–131
 - detection 8: 125–126
 - eclampsia 8: 129–130
 - labour 8: 130–131
 - management 8: 126–129
 - when to hospitalise 8: 126
 - mild: treatment 7: 152–153
- Hyperthyroidism
 - β -blocking drugs 7: 48–54

Hypertrichosis
due to corticosteroids 8: 75

Hypnotic drugs
use in elderly 8: 136-137

Hypoglycaemia
 β -blocking drugs 7: 126

I

Imipramine
withdrawal symptoms 7: 473
Imipramine poisoning
in children 7: 470-471
Immunosuppressive drugs
liver disease 8: 139-145
Immunotherapy 8: 401-404, 405-407
active 8: 413
clinical experience 8: 414
problems in implementation 8: 414-416
adoptive 8: 412-413
bone marrow transplants 8: 412-413
transfusion of lymphocytes 8: 412
current status 8: 411-416
passive 8: 412

Indomethacin
ankylosing spondylitis 8: 453

Inpea
angina pectoris 7: 63
hypertension 7: 94

Insomnia
treatment in elderly 8: 136-137

Intrauterine device
see contraceptive device

Isotiazid
dosage in renal failure 7: 466-467

Isoprenaline
asthma
pharmacology 7: 360

Isosorbide
angina pectoris
 β -blocking drugs 7: 76-78

J

Joint disease, amyloid
treatment 7: 149

K

Kerato-conjunctivitis, vernal
cromoglycate 7: 294

Keratolytic agents
benzoyl peroxide 8: 417-421

Ketamine
compared with alfathesin 8: 95-96

Ketoprofen 8: 168-175
animal pharmacology 8: 172-173
clinical trials 8: 169-172
osteoarthritis 8: 171-172
rheumatic diseases 8: 172
rheumatoid arthritis 8: 169-171
dosage 8: 174

drug interactions 8: 174
pharmacokinetics 8: 173
side-effects 8: 173

L

Laboratory control
anticonvulsant therapy 8: 386-397

Labour, induction
prostaglandins 8: 197-199

Leukaemia, acute
epidemiology of long-term survival 8: 317-318
treatment
immunotherapy 8: 411-415

Levodopa
Parkinson's disease 7: 474-475

Libido
 β -blocking drugs 7: 101

Lipid metabolism
drug action 7: 141-142

Liquorice, deglycyrrhizinised
see deglycyrrhizinised liquorice

Lithium
side-effects
 β -blocking drugs 8: 121
use in elderly 8: 134-135

Liver disease
 β -blocking drugs 7: 45
treatment with corticosteroids 8: 139-145

Lupus erythematosus
corticosteroids 8: 443-444
practolol 7: 102

Lymphoma: treatment
immunotherapy 8: 411-416

M

Magnesium ammonium phosphate stones
see renal calculi

Mammography 8: 310-311

Mania
treatment in elderly 8: 134-135

Mast cell
asthma 7: 353-355
cromoglycate 7: 188-191

Mefruside
dosage 7: 425
pharmacology 7: 420-422
diuretic effect 7: 420
hypotensive effect 7: 421
metabolic effects 7: 421-422
site of action 7: 420-421
side-effects 7: 424-425
therapeutic efficacy 7: 422-424
hypertension 7: 423-424
oedema 7: 422-423

Meningitis
age incidence 8: 19-21
causative organisms 8: 19-21
mortality and morbidity rates 8: 17-19
neonatal meningitis 8: 46-48
persistent fever 8: 41
pre-disposing causes 8: 22-23

- altered immune state 8: 23
 - CNS congenital anomalies 8: 22
 - primary infection elsewhere 8: 22-23
 - sex 8: 22
 - socio-economic status 8: 22
 - rare meningitides 8: 48
 - rehabilitation 8: 41-42
 - Meningitis: diagnosis 8: 23-29
 - cerebrospinal fluid examination 8: 25
 - clinical presentation 8: 23-25
 - counter-immunoelectrophoresis 8: 26
 - culture 8: 25
 - differential cell count 8: 25
 - enzyme estimations 8: 26
 - glucose determination 8: 25-26
 - immunoglobulin levels 8: 28
 - limulus lysate 8: 28
 - nitroblue tetrazolium dye test 8: 28
 - prior antibiotic treatment 8: 28-29
 - protein level 8: 26
 - Meningitis: treatment 8: 29-48
 - general considerations 8: 29-37
 - bactericidal and bacteriostatic drugs 8: 30-33
 - bacteriological considerations 8: 29-33
 - pharmacokinetics 8: 33-37
 - sensitivity of infecting organisms 8: 29-30
 - initial treatment 8: 37-38
 - anticonvulsants 8: 38
 - cerebral oedema 8: 38
 - choice of antibacterial drug 8: 37
 - corticosteroids 8: 38
 - shock 8: 38
 - monitoring its effectiveness 8: 40-41
 - specific infections 8: 42-46
 - H. influenza meningitis 8: 42-44
 - meningococcal meningitis 8: 44-45
 - pneumococcal meningitis 8: 45-46
 - staphylococcal meningitis 8: 46
 - streptococcal meningitis 8: 46
 - supportive treatment 8: 39-40
 - accompanying infection 8: 39
 - biochemical abnormalities 8: 40
 - general measures 8: 39
 - hydrocephalus 8: 40
 - subdural effusions 8: 39-40
 - Meniere's disease
 - treatment 7: 306-308
 - Meningococcal meningitis
 - see meningitis
 - Metaproterenol
 - see orciprenaline
 - Methohexitone
 - compared with alfathesin 8: 90, 92, 95, 97
 - Methotrexate
 - effect on liver 8: 151
 - psoriasis 8: 151
 - Methoxyflurane
 - nephrotoxicity 7: 400-403
 - Methylxanthines
 - pharmacology 7: 361-362
 - mode of action 7: 193-194
 - Metiamide
 - peptic ulcer 8: 226-227
 - Micro-organisms, gastro-intestinal
 - drug metabolism 8: 227
 - Mithramycin
 - adverse effects 8: 273
 - dosage 8: 271-272
 - duration of effect 8: 272
 - in metabolic bone disease
 - efficacy 8: 272-273
 - method of administration 8: 271-272
 - mode of action 8: 269-271
 - Multiple sclerosis
 - see sclerosis, multiple
 - Myocardial infarction
 - β -blockers 7: 442-446
 - effect of catecholamines 7: 442
 - prophylactic use 7: 443
 - therapeutic regimen 7: 445
 - therapeutic use 7: 443-445
 - contraceptives, oral 7: 142-143
 - management in diabetes 8: 237
- N
- Nasal obstruction
 - antigen-induced
 - cromoglycate 7: 198-200
 - Nasal polyps
 - cromoglycate 7: 295
 - Neonate
 - meningitis 8: 46-48
 - phenytoin 7: 392-393
 - Nephrolithiasis
 - treatment
 - phosphate 8: 275
 - Nephrotic syndrome, minimal lesion
 - corticosteroids 8: 440-443
 - Nephrotoxicity
 - aspirin 8: 238
 - enflurane 8: 230-231
 - methoxyflurane 7: 400-403
 - Nitrates
 - angina pectoris
 - β -blocking drugs comparison 7: 76-78
 - Nitroblue tetrazolium dye test
 - meningitis 8: 28
 - Nitrous oxide
 - effect on psychomotor skills 8: 318-319, 461-462
- O
- Obesity
 - adipose tissue metabolism 7: 321-322
 - high-protein diet 7: 148-149
 - Obstetrics
 - alfathesin 8: 93
 - prostaglandins 8: 161-163
 - Oestrogen
 - effects after hysterectomy 8: 464-465
 - Oestrogens
 - acne vulgaris 8: 218
 - adverse reactions 7: 469-470
 - clinical applications
 - metabolic bone disease 8: 268-269

- mode of action 8: 268
- Oncogenesis
with anticonvulsants 8: 309
- Orciprenaline
asthma
 pharmacology 7: 360
corticosteroid injection 8: 316–317
- Osteoarthritis
ketoprofen 8: 171–172
- Osteomalacia
confused with osteoporosis 8: 298
management 8: 246–247
treatment 8: 250–289
 vitamin D 8: 264–265
- Osteoporosis
conditions confused with osteoporosis 8: 298–299
 multiple myeloma 8: 298
 osteomalacia 8: 298
 primary hyperparathyroidism 8: 298–299
 secondary carcinoma 8: 298
 trauma 8: 299
diagnosis 8: 292–297
epidemiology 8: 290–291
management 8: 247
presentation 8: 291–292
- Osteoporosis: treatment 8: 250–289, 299–302, 302–305
anabolic hormones 8: 304
calcitonin 8: 261, 304
calcium 8: 279, 302
clinical considerations 8: 299–300
diphosphonates 8: 277, 305
drugs of unproven benefit 8: 304–305
fluoride 8: 280, 303–304
general measures 8: 302
hormones 8: 268–269
pharmacological and physiological considerations 8:
 301–302
 fluoride 8: 301–302
 normal and osteoporotic bone 8: 301
 role of androgens 8: 301
 role of oestrogens 8: 301
 suppression of parathyroids 8: 301
phosphate 8: 275, 304
prophylactic therapy 8: 305–306
 anabolic hormones 8: 305
 calcium 8: 305–306
 general measures 8: 305
 oestrogen 8: 305
vitamin D 8: 302–303
- Oxprenolol
absorption 7: 40
angina pectoris 7: 61, 67
arrhythmias 7: 453
asthma 7: 132–136
bioavailability 7: 40–41
cardiomyopathy, hypertrophic 7: 107–109
clearance 7: 42–43
half-life, excretion 7: 42–43
elimination 7: 40
heart syndrome, hyperkinetic 7: 110
hypertension 7: 91–92, 96–98, 8: 422–431
hyperthyroidism 7: 50
pharmacodynamics 7: 8–38
respiratory function 7: 130–136
side-effects 7: 98–102, 127
- Oxyphenbutazone
ankylosing spondylitis 8: 453
- P
- Paget's disease
management 8: 247–248
treatment 8: 250–289
 calcitonin 8: 259–261
 diphosphonates 8: 277
 mithramycin 8: 272–273
- Paracetamol overdosage
treatment with cysteamine 8: 457–458
- Paracetamol poisoning
charcoal 7: 139
cholestyramine 7: 139
- Parathyroid hormone
metabolic bone disease 8: 253–256
- Parkinson's disease
levodopa 7: 474–475
- Paronychia, candidal 8: 465
- D-Penicillamine
renal calculi 8: 68
- Penicillins
amoxycillin 7: 326–336
- Pentazocine
central nervous system effects 8: 149–150
colonic response 8: 150–151
side-effects 8: 149–150
- Peptic ulcer
antacids 8: 224–225
liquorice, deglycyrrhizinised 8: 331–336
- Pertussis inoculation
neurological complications 8: 310
- Pheniramine
hallucinations with 7: 471–472
- Phenothiazines
use in elderly 8: 135–136
- Phenylbutazone
ankylosing spondylitis 8: 453
- Phenytoin
adverse reactions 7: 395–396
dosage in children 7: 392–393
dosage, loading 7: 393–394
dosage, maintenance 7: 393–394
laboratory control of dosage 8: 386–397
plasma levels 7: 393–394
- Phenytoin: dysmorphic potential 8: 340–353
animal investigations 8: 341–345, 362
 in monkeys 8: 345
 in rodents 8: 341–345
clinical investigations 8: 345–350
folic acid metabolism 8: 363
mechanism of effect 8: 350–353, 362–364
practical implications 8: 364–365
related to folic acid deficiency 8: 352–353
- Phosphate
adverse effects 8: 276
clinical applications
 metabolic bone disease 8: 274–275

- dosage 8: 275
mode of action 8: 274
mode of administration 8: 275
- Pindolol**
absorption 7: 40
angina pectoris 7: 62, 72, 77
arrhythmias 7: 453–454
asthma 7: 132–136
bioavailability 7: 40–41
clearance 7: 42–43
elimination 7: 40
half-life, excretion 7: 42–43
hypertension 7: 93, 96–98, 8: 422–431
hyperthyroidism 7: 51
pharmacodynamics 7: 8–38
renal disease: elimination 7: 45
respiratory function 7: 130–136
side-effects 7: 98–102, 127
- Placental transfer**
cromoglycate 7: 209
- Plasma levels**
anticonvulsants 8: 390–394
- Pneumococcal meningitis**
see meningitis
- Polyarteritis nodosa**
corticosteroids 8: 444
- Porphyria cutanea tarda**
chloroquine 8: 152
- Potassium, intravenous**
tricyclic antidepressant overdosage 8: 436
- Practolol**
absorption 7: 40
angina pectoris 7: 63, 73, 74–75
arrhythmias 7: 454–455
asthma 7: 132–136
bioavailability 7: 40–41
cardiomyopathy, hypertrophic 7: 107–109
clearance 7: 42–43
elimination 7: 40
half-life, excretion 7: 42–43
heart syndrome, hyperkinetic 7: 114
hypertension 7: 91, 96–98, 8: 422–431
hyperthyroidism 7: 51
lupus erythematosus 7: 102
pharmacodynamics 7: 8–38
psychiatry 8: 109–124
renal disease: elimination 7: 45
respiratory function 7: 130–136
side-effects 7: 98–102
- Prednisolone**
compared with beclomethasone 8: 315–316
hepatitis 8: 140–141
- Pregnancy**
bacteruria 8: 59
dysmorphic potential of phenytoin 8: 340–353
hypertension 8: 125–131
outcome in epileptic women 8: 356–358
- Procainamide**
plasma levels and dosage 8: 456–457
sustained release tablet
dosage 8: 457
- Pronethalol**
angina pectoris 7: 61, 67
- Fallot's tetralogy 7: 115
hyperthyroidism 7: 49
respiratory function 7: 134–135
- Propanidol**
compared with alfathesin 8: 90, 97
side-effects 8: 82
- Propranolol**
absorption 7: 40
alcoholism 7: 140
angina pectoris 7: 61, 69–72, 74–78
arrhythmias 7: 451–452
asthma 7: 124–125, 132–136
bioavailability 7: 40–41
cardiac failure 7: 122
cardiomyopathy, hypertrophic 7: 107–109
clearance 7: 42–43
elimination 7: 40
Fallot's tetralogy 7: 114–115
haematological reactions 7: 126
half-life, excretion 7: 42–43
heart syndrome, hyperkinetic 7: 110–114
hypertension 7: 90, 94, 96–98, 8: 422–431
hyperthyroid crisis 7: 52
hyperthyroidism 7: 49–50, 52–53
hypoglycaemic reactions 7: 126
metabolism 7: 41–42
pharmacodynamics 7: 8–38
plasma binding 7: 43
psychiatric effects 7: 100–101, 125
psychiatry 8: 109–124
renal disease: elimination 7: 45
respiratory function 7: 130–136
side-effects 7: 98–102, 118–127, 130–137
- Prostaglandins** 8: 176–207
potential clinical uses 8: 200–202
asthma 8: 201
cardiovascular therapeutics 8: 200–201
gastric ulcers 8: 201–202
nasal congestion 8: 202
therapeutic use
asthma 7: 352–353
obstetrics 8: 161–163, 164–167
- Prostaglandins: clinical use** 8: 197–200
induction of labour 8: 197–199
prostaglandin E₂ 8: 198
prostaglandin F_{2α} 8: 197–198
safety of prostaglandins 8: 198–199
therapeutic abortion 8: 199–200
cervical dilatation 8: 200
extra-amniotic administration 8: 199–200
intra-amniotic administration 8: 199
missed abortion 8: 200
vaginal administration 8: 200
- Prostaglandins: human reproduction** 8: 186–197
fertilisation 8: 189
in the female 8: 188–197
in the male 8: 186–188
erection and ejaculation 8: 186–187
male fertility 8: 187–188
intercourse and premature labour 8: 195–196
intrauterine device 8: 196–197
luteolysis 8: 191–194
menstruation 8: 191

- ovulation 8: 189-191
 - physiological roles 8: 186
 - sperm transport 8: 188-189
 - spontaneous abortion 8: 194-195
 - umbilical cord 8: 196
 - Prostaglandins: pharmacology 8: 181-186
 - cardiovascular system 8: 182
 - eye 8: 184
 - gastrointestinal function 8: 184-185
 - platelet aggregation 8: 182-183
 - renal system 8: 182
 - respiratory system 8: 181
 - role in inflammation 8: 183-184
 - Protein binding
 - amoxycillin 7: 330
 - Protein intolerance
 - gastro-intestinal
 - cromoglycate 7: 293-294
 - Proteinuria
 - in pregnancy 8: 127
 - Pteriasis
 - fluocinonide 7: 341
 - methotrexate 8: 151
 - Psychiatric disorders
 - in the elderly 8: 133
 - Psychiatry
 - alfathesin 8: 92
 - Psychotherapeutic drugs
 - use in the elderly 8: 132-138
 - anxiety states 8: 136
 - depression 8: 134
 - general principles 8: 132-133
 - insomnia 8: 136-137
 - mania 8: 134-135
 - organic psychoses 8: 136
 - schizophrenia 8: 135-136
 - Pulsus paradoxus
 - asthma 7: 375
 - Purpura
 - due to food additives 8: 234
 - Pustulosis palmaris et plantaris
 - tetracycline 7: 476-477
- Q
- Quinidine
 - DC cardioversion 7: 446-447
- R
- Raynaud's phenomenon
 - β -blocking drugs 7: 101
 - Renal calculi
 - aetiology 8: 62-63
 - pathogenesis 8: 63-64
 - treatment 8: 62-69
 - treatment: general 8: 62-65
 - hydration control 8: 65
 - urinary infection control 8: 65
 - role of surgery 8: 64
 - treatment: specific 8: 65-69
 - calcium stones 8: 65-67
 - cystine stones 8: 68
 - hyperoxaluria 8: 68-69
 - magnesium ammonium phosphate stones 8: 67
 - uric acid stones 8: 67-68
- Renal disease
 - β -blocking drugs 7: 45
 - corticosteroids 8: 438-447
- Renal failure
 - high dose frusemide 7: 475-476
 - isoniazid dosage 7: 466-467
- Renal failure, acute
 - treatment 7: 155-156
- Renal transplant
 - corticosteroids 8: 445
- Renin activity
 - β -blocking drugs 8: 463
- Renin secretion
 - β -blocking drugs 7: 30
- Reproduction, human
 - role of prostaglandins 8: 186-197
- Respiration, control of
 - asthma 7: 355-357
- Respiratory function
 - β -blocking drugs 7: 130-138
- Respiratory infections
 - amoxycillin 7: 331-332
- Rheumatoid arthritis
 - therapy
 - corticosteroid injection 8: 316-317
 - gold 7: 399
 - ketoprofen 8: 169-171
- Rhinitis, allergic
 - cromoglycate 7: 283-293
- Rhinitis, perennial
 - cromoglycate 7: 291-293
- Rhonchi
 - asthma 7: 374
- Rifampicin
 - causing hepatitis 8: 228-229
 - side-effects 8: 148-149
- Rubella
 - in pregnancy 8: 153-154
- S
- Salbutamol
 - asthma
 - pharmacology 7: 361
 - Salicylazosulphapyridine
 - adverse reactions 7: 462-463
 - metabolism 7: 463-464
 - in health 7: 463-464
 - in ulcerative colitis 7: 463-464
 - Schizophrenia
 - β -blocking drugs 8: 120-121
 - treatment in elderly 8: 135-136
 - Sclerosis, multiple
 - baclofen 8: 4-8
 - Sepsis, gram-negative
 - gentamicin therapy 8: 307-308
 - Serotonin
 - asthma 7: 353
 - Skin cancer
 - urea treatment 8: 155-156, 233

Sodium bicarbonate
tricyclic antidepressant overdosage 8: 436

Sodium cromoglycate
see cromoglycate, sodium

Sodium cromolyn
see cromoglycate, sodium

Sodium excretion
 β -blocking drugs 7: 29–30

Sotalol
angina pectoris 7: 63, 72, 76
hypertension 7: 94
hyperthyroidism 7: 51
pharmacodynamics 7: 8–38
psychiatry 8: 109–124

Spasticity
baclofen 8: 4–8

Spirometric measurements
asthma 7: 375

Sulphates
metabolic bone disease 8: 278

Sympathomimetic amines
asthma
pharmacology 7: 358–361

Systemic lupus erythematosus
see lupus erythematosus

T

Tachycardia, sinus
 β -blockers 7: 433

Tachycardia, supraventricular
 β -blockers 7: 434–436

Tachycardia, ventricular
 β -blockers 7: 440–442

Terbutaline
asthma
pharmacology 7: 360

Tetrabenazine
in chorea 7: 477–478

Tetracycline
bioavailability 7: 465–466
pustulosis palmaris et plantaris 7: 476–477

Therapeutic levels
anticonvulsants 8: 390–391

Thermography 8: 311

Thiopentone
compared with alfathesin 8: 88–90, 93, 95, 97
side-effects 8: 82–83

Thrombo-embolism
contraceptives, oral 7: 143–144
prevention after myocardial infarction 8: 152–153

Timolol
hypertension 8: 422–431

Tiprenolol
respiratory function 7: 134–135

Toxic levels
anticonvulsants 8: 391–392

Trauma
confused with osteoporosis 8: 299

Tremor
 β -blocking drugs 8: 121

Tricyclic antidepressants
see antidepressants, tricyclic

Tuberculosis, pulmonary
treatment 7: 481

U

Urea
skin cancer 8: 155–156, 233

Uric acid stones
see renal calculi

Uricosuric action
halofenate 8: 146

Urinary tract infection 8: 54–61
amoxycillin 7: 332–333

diagnosis 8: 54–56
suprapubic aspiration 8: 55–56
urine specimen 8: 55

follow-up 8: 61
treatment 8: 56–59

acute attack 8: 56–57
in the male 8: 59

in pregnancy 8: 59
recurrent attacks 8: 57–59

in renal impairment 8: 59
who and when to investigate 8: 59–61

Urine tests 8: 55

V

Varicose ulcers
eczema 8: 231–233

management 8: 231–233
treatment 8: 156–157

Vasodilators
+ β -blocking drugs in hypertension 7: 94, 8: 409

Vehicles, dermatological
fluocinonide 7: 337–343

Verapamil
angina pectoris
 β -blocking drugs comparison 7: 78

Vertigo
causes 7: 302–304

examination 7: 304
history 7: 298

treatment 7: 305–309

Vitamin D
metabolic bone disease 8: 264–265

mode of action 8: 262–264
bone 8: 263

gastro-intestinal tract 8: 263
kidney 8: 264

preparations 8: 265

Vitamin E
epidermolysis bullosa 8: 319, 462

W

Weight gain
amitriptyline 8: 229–230

β -blocking drugs 7: 102

X

Xerography 8: 310–311

Drugs

International Journal of Current Therapeutics and Applied Pharmacology Reviews, featuring Evaluations on New Drugs, Review Articles on Drugs and Drug Therapy, and Drug Literature Abstracts

<i>Editor</i>	<i>G.S. Avery</i>	<i>F.C. Hollows, Sydney</i>
<i>Associate Editors</i>	<i>R.N. Brogden</i> <i>D.N. McDonald</i> <i>Rosalind Spencer</i> <i>T.M. Speight</i>	<i>C. McK. Holmes, Dunedin</i> <i>W.R. Holmes, Christchurch</i> <i>R.N. Howie, Auckland</i> <i>H.K. Ibbertson, Auckland</i> <i>L.B. Jellet, Perth</i> <i>Priscilla Kincaid-Smith, Melbourne</i>
<i>Assistant Editor</i>	<i>I.W. Davey</i>	<i>J.W. Lance, Sydney</i> <i>J.H. Lee, Sydney</i> <i>Str William Lilley, Auckland</i>
<i>Chief Consulting Editor</i>	<i>G.S. McL. Kellaway</i>	<i>P.J. Little, Christchurch</i> <i>W.J. Louis, Victoria</i> <i>A.D. Macalister, Dunedin</i>
<i>Consulting Editors</i>	<i>T.F. Acheson, Sydney</i> <i>J.W. Ardagh, Christchurch</i> <i>R.R. Bailey, Christchurch</i> <i>J.A. Baird, Wellington</i> <i>Sir Brian Barratt-Boyes, Auckland</i> <i>R.W. Beal, Adelaide</i> <i>D.W. Beaven, Christchurch</i> <i>R.F.A. Becke, Sydney</i> <i>D.G. Bonham, Auckland</i> <i>J.S. Boyd-Wilson, Wellington</i> <i>E.P. Brasted, Auckland</i> <i>D.A. Bremner, Auckland</i> <i>J.G. Buchanan, Auckland</i> <i>Patricia Buckfield, Dunedin</i> <i>R. Carruthers, Launceston</i> <i>D.S. Cole, Auckland</i> <i>W.H.J. Cole, Melbourne</i> <i>J.F. Copplestone, Geneva</i> <i>J.M. Court, Melbourne</i> <i>L.W. Cox, Adelaide</i> <i>Marion D. Cridland, Sydney</i> <i>J.A.K. Cunningham, Christchurch</i> <i>M.H.L. de Groot, Toowoomba</i> <i>I.S. de la Lande, Adelaide</i> <i>P.B. Doak, Auckland</i> <i>A.E. Doyle, Melbourne</i> <i>M.J. Eadie, Brisbane</i> <i>Keitha Farmer, Auckland</i> <i>D.W. Feeney, Auckland</i> <i>T. Gebbie, Wellington</i> <i>G.H. Green, Auckland</i> <i>D.R. Hay, Christchurch</i> <i>P.B. Herdson, Auckland</i> <i>G.C. Hitchcock, Auckland</i>	<i>J.B. Mackay, Wellington</i> <i>E.G. McQueen, Dunedin</i> <i>D.S. Malcom, Dunedin</i> <i>G. Milner, Melbourne</i> <i>O.R. Nicholson, Auckland</i> <i>J.D.K. North, Auckland</i> <i>K.P. O'Brien, Auckland</i> <i>R.G. Park, Wellington</i> <i>D.W. Piper, Sydney</i> <i>W.M. Platts, Christchurch</i> <i>D.E. Poswillo, London</i> <i>L.W. Powell, Brisbane</i> <i>M.J. Purdy, Hamilton</i> <i>M.J. Rand, Melbourne</i> <i>P.C. Reade, Melbourne</i> <i>R.G. Robinson, Sydney</i> <i>B.S. Rose, Hamilton</i> <i>W.S. Rose, Brisbane</i> <i>N. Roydhouse, Auckland</i> <i>M.J.W. Sando, Adelaide</i> <i>R.J. Seddon, Auckland</i> <i>F.O. Simpson, Dunedin</i> <i>B.N. Singh, Auckland</i> <i>J.G. Sloman, Melbourne</i> <i>B.C. Stratford, Melbourne</i> <i>P. Taft, Melbourne</i> <i>C. Tasman Jones, Auckland</i> <i>J. Tonkin, Sydney</i> <i>J.H. Tyrer, Brisbane</i> <i>A.M.O. Veale, Dunedin</i> <i>D.N. Wade, Sydney</i> <i>J.M. Watt, Dunedin</i> <i>F.A. Whitlock, Brisbane</i> <i>R. Zacest, Woodville</i>



Australasian Drug Information Services Pty. Ltd. Sydney

Australasian Drug Information Services Pty. Ltd., P.O. Box 194,
Balgowlah/Sydney, NSW 2093 (Australia)

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording or by any information storage and retrieval system, without permission in writing from the publishers.

© Copyright 1974 by Australasian Drug Information Services Pty. Limited, Sydney
Printed in Switzerland by Thür AG Offsetdruck, Pratteln

Contents

Guest Editorials

<i>Bookallil, M.J.</i> (Sydney): Anaesthesia in the hypertensive Patient	84-86
<i>Burns, M.M. and Eastman, C.J.</i> (Sydney): What Form of Steroid Therapy in Severe Chronic Asthma	241-245
<i>Coates, A.</i> (Melbourne): Current Status of Immunotherapy	405-407
<i>Gibb, D.B.</i> (Sydney): Sensitivity to Anaesthetics	81-83
<i>Henley, J.W. and Ibbertson, H.K.</i> (Auckland): Current Concepts in the Medical Management of Metabolic Bone Disease	246-249
<i>Liggins, G.C.</i> (Auckland): Prostaglandins: Current Therapeutic Status in Obstetrics	161-163
<i>Smith, I.D.</i> (Sydney): Prostaglandins: Current Therapeutic Status in Obstetrics	164-167
<i>Wilson, J.D.</i> (Auckland): Immunotherapy for Cancer	401-404
<i>Zacest, R.</i> (Adelaide): β -Adrenoreceptor Blocking Drugs in Hypertension	408-410

Special Articles

<i>Herxheimer, A.</i> (London): Drug Information: Is there a Need for International Uniformity?	321-329
<i>Mathé, G.</i> (Villejuif): Current Status of Immunotherapy of Human Cancers: Leukaemias, Lymphomas, Solid Tumours	411-416

Evaluations on New Drugs

<i>Brogden, R.N.; Speight, T.M. and Avery, G.S.</i> (Auckland): Baclofen: A Preliminary Report of its Pharmacological Properties and Therapeutic Efficacy in Spasticity	1-14
<i>Brogden, R.N.; Speight, T.M. and Avery, G.S.</i> (Auckland): Alfathesin ('Alfathesin' - Glaxo): An Independent Report	87-108
<i>Brogden, R.N.; Speight, T.M. and Avery, G.S.</i> (Auckland): Ketoprofen: A Preliminary Report of its Pharmacological Activity and Therapeutic Efficacy in Rheumatic Disorders	168-175
<i>Brogden, R.N.; Speight, T.M. and Avery, G.S.</i> (Auckland): Caved-S: A Report of its Pharmacological Properties and Therapeutic Efficacy in Peptic Ulcer	330-339
<i>Brogden, R.N.; Speight, T.M. and Avery, G.S.</i> (Auckland): Benzoyl Peroxide Acne Lotions: An Independent Report	417-421

Review Articles

<i>Doyle, A.E.</i> (Heidelberg): Use of β -Adrenoreceptor Blocking Drugs in Hypertension	422-431
<i>Eadie, M.J.</i> (Brisbane): Laboratory Control of Anticonvulsant Dosage	386-397
<i>Hambleton, G. and Davies, Pamela A.</i> (London): Diagnosis and Management of Bacterial Meningitis	15-53
<i>Karim, S.M.M.</i> (Singapore) and <i>Hillier, K.</i> (England): Prostaglandins: Pharmacology and Clinical Application	176-207

<i>Mercier-Parot, L. and Tuchmann-Duplessis, H. (Paris): The Dysmorphogenic Potential of Phenytoin: Experimental Observations</i>	340-353
<i>Mundy, G.R. and Raisz, L.G. (New York): Drugs for Disorders of Bone: Pharmacological and Clinical Considerations</i>	250-289
<i>Norris, J.W. and Pratt, R.F. (Toronto): Folic Acid Deficiency and Epilepsy</i>	366-385
<i>Speidel, B.D. and Meadow, S.R. (Bristol): Epilepsy, Anticonvulsants and Congenital Malformations</i>	354-365
<i>Whitlock, F.A. and Price, J. (Brisbane): Use of β-Adrenergic Receptor Blocking Drugs in Psychiatry</i>	109-124

Practical Therapeutics

<i>Bailey, R.R. (Christchurch): The Problem of Recurrent Urinary Tract Infections</i>	54-61
<i>Carruthers, R. (Launceston): Acne Vulgaris: Pathogenesis and Treatment</i>	217-223
<i>Caughey, D.E. (Auckland): Management of Ankylosing Spondylitis</i>	448-455
<i>De Groot, M.H.L. (Brisbane): The Clinical Use of Psychotherapeutic Drugs in the Elderly</i>	132-138
<i>Fung, W.P. (Singapore): Clinical Use of Corticosteroid and Immunosuppressive Drugs in Liver Disease</i>	139-145
<i>Ingham, Joan (Sydney): Osteoporosis: Diagnosis and Treatment</i>	290-306
<i>Lawrence, J.R. (Adelaide): Clinical Use of Corticosteroids in Renal Disease</i>	438-447
<i>Martin, J.D. (Nedlands): The Management of Hypertensive Disease of Pregnancy</i>	125-131
<i>Mathew, T. (Melbourne): Treatment of Renal Calculi</i>	62-69
<i>Purdy, M.J. (Hamilton): Adverse Effects of Strong Topical Corticosteroids</i>	70-77
<i>Reynolds, J.L. (Auckland): A Practical Approach to the Management of Angina</i>	208-216
<i>Vohra, J. and Burrows, G.D. (Melbourne): Cardiovascular Complications of Tricyclic Anti-depressant Overdosage</i>	432-437

Drug Literature Abstracts	146, 224, 307, 456
-------------------------------------	--------------------

Subject Indices	78, 158, 239, 318, 398, 466
---------------------------	-----------------------------

Data Processing in Medicine Datenverarbeitung in der Medizin

*Series Editor: R. Richterich † (Bern)

François Wider (Lausanne)

Vol. 3 **Psychoactive Drugs** including Combinations

Psychoaktive Stoffe und Kombinationspräparate
Substances psychoactives et préparations combinées

XX + 264 p., 1974

SFr. 120.- / US \$ 44.00 / DM 114.- / £ 17.50

ISBN 3-8055-1740-8

Psychoactive Drugs bridges the gap in the psychopharmacological literature and should prove invaluable as a reference work for all specialists in the study of psychopharmacology

Psychoactive Drugs covers more than 650 substances according to clinical and therapeutical indications

Psychoactive Drugs is separated, for ease of reference into five major groups:

Neuroleptics, Antidepressants, Psychodysleptics

Tranquillizers, Psychostimulants,

Psychoactive Drugs specifies, whenever possible, each substance with the International Nonproprietary Name recommended by WHO in addition to the trivial name, abbreviated formulae, structural formulae and trade name

Psychoactive Drugs contains, for ease of localization, an alphabetical index (approx. 7,000 references) as well as an abbreviated formulae register)



S. Karger · Basel · München · Paris · London · New York · Sydney

General Information

Publication data: Two volumes of *Drugs* are published annually. Each volume comprises six 80-page issues. Subscription price per volume SFr. 135. - / US \$49.00 / DM128. - / £19.60 including postage. Multiple subscription rates on request. *Drugs* is published by Australasian Drug Information Services Pty. Ltd., 559 Sydney Road, Seaford, N.S.W. Australia.

Subject index: Each issue has its own comprehensive subject index which is cumulated in issue No. 6 of the second volume in each year.

Editorial matter is prepared by our own professionally qualified editorial staff and by honorary specialist consultants from all fields of medicine. While great care has been taken in compiling and checking the information contained in *Drugs*, the publisher cannot accept any responsibility for errors or omissions. The inclusion or exclusion of any product does not mean that the publisher advocates or rejects its use either generally or in any particular field or fields.

Drug nomenclature: Approved names of the British Pharmacopoeia Commission are used throughout the text. When the Commission has not adopted a name for the drug under discussion, the United States Adopted Name (USAN - United States Pharmacopoeial Convention Inc) or the International Non-Proprietary Name (INN - WHO) is used. When available, all three names are given at the head of the evaluations on new drugs and review article sections, and elsewhere in the text as appropriate. Other synonyms (e.g. research code names of new drugs) are also given.

Correspondence: Letters to the editor are welcomed. They should be submitted in duplicate type-written on one side of the paper only and double-spaced with a wide margin. They should be of reasonable length and written in English. Letters will be published if found suitable and will be subject to editorial review and possible abridgement.

Manuscripts: Information on the preparation of manuscripts will be provided to authors.

Copyright: © 1974 ADIS Press. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying or recording or by any information storage and retrieval system, without permission in writing from the publishers.

Subscription

Subscription orders can be placed with any bookstore or direct with the distributors S. Karger AG, Arnold-Böcklin-Strasse 25, CH-4011 Basel (Switzerland), or else with the following:

Subscription Order Form	
Please enter my subscription for <i>Drugs</i> beginning with	
<input type="checkbox"/> Vol. 1, 1971	<input type="checkbox"/> Vol. 4, 1972 <input type="checkbox"/> Vol. 7, 1974
<input type="checkbox"/> Vol. 2, 1971	<input type="checkbox"/> Vol. 5, 1973 <input type="checkbox"/> Vol. 8, 1974
<input type="checkbox"/> Vol. 3, 1972	<input type="checkbox"/> Vol. 6, 1973
Name _____	
Title _____	
Address _____	
City _____	
State/Zip _____	
Bundesrepublik Deutschland: S. Karger GmbH, Postfach 2, D-8034 Germering/München	
France: S. Karger S.A., 42bis, Bd de La Tour-Maubourg, F-75 Paris 7e	
Great Britain: John Wiley and Sons Ltd., Baffins Lane, Chichester, Sussex	
USA: Albert J. Phiebig Inc., US Representative of S. Karger, P.O. Box 352, White Plains, NY 10602	
Australia: Australasian Drug Information Services Pty. Ltd., Agents in Australasia for S. Karger, P.O. Box 194, Balgowlah/Sydney, NSW 2093	
New Zealand: Australasian Drug Information Services Pty. Ltd., New Zealand Office, P.O. Box 34-030, Birkenhead, Auckland 10	

